Wells Fargo analyst Sam Reid maintained a Buy rating on DR Horton (DHI – Research Report) today and set a price target of $180.00. The company’s shares closed last Friday at $158.52.
According to TipRanks, Reid is a 4-star analyst with an average return of 12.2% and a 68.57% success rate. Reid covers the Consumer Cyclical sector, focusing on stocks such as KB Home, Mohawk, and DR Horton.
In addition to Wells Fargo, DR Horton also received a Buy from Citi’s Anthony Pettinari in a report issued on April 5. However, on April 2, Wedbush downgraded DR Horton (NYSE: DHI) to a Sell.
The company has a one-year high of $165.75 and a one-year low of $94.38. Currently, DR Horton has an average volume of 2.54M.
Based on the recent corporate insider activity of 71 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DHI in relation to earlier this year. Last month, Barbara K. Allen, a Director at DHI sold 203.00 shares for a total of $30,967.65.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
DR Horton (DHI) Company Description:
Founded in 1978, Texas-based D.R. Horton, Inc. is a homebuilding company that is engaged in the construction and sale of single-family homes through its diverse brand portfolio that includes D.R. Horton, Emerald Homes, Express Homes and Freedom Homes.
Read More on DHI:
- Forestar Group (NYSE:FOR): An Attractive Investment Amid Anticipated Housing Uptick
- D.R. Horton price target raised to $191 from $166 at Citi
- D.R. Horton price target raised to $186 from $166 at Barclays
- Estee Lauder upgraded, Petco downgraded: Wall Street’s top analyst calls
- Wedbush more bearish on D.R. Horton, downgrades to Underperform
